| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Antibody |
| Molecule Category: | UNKNOWN |
| UNII: | 7K5O7P6QIU |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| BINDING AGENT | B-lymphocyte antigen CD19 binding agent |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Lymphoma, B-Cell | 4 | D016393 | FDA |
| Lymphoma, Mantle-Cell | 2 | D020522 | ClinicalTrials |
| Lymphoma, Non-Hodgkin | 2 | D008228 | ClinicalTrials |
| Lymphoma, Follicular | 2 | D008224 | ClinicalTrials |
| Lymphoma, Follicular | 2 | D008224 | ClinicalTrials |
| Waldenstrom Macroglobulinemia | 2 | D008258 | ClinicalTrials |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | D054198 | ClinicalTrials |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | D015451 | ClinicalTrials |
| Burkitt Lymphoma | 1 | D002051 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| ChEMBL | CHEMBL4297778 |
| FDA SRS | 7K5O7P6QIU |
CONTENTS